FDA
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
-
-
-
-
-
-
-
Tenax Therapeutics (TENX) Prices Prices 8.67M Share Offering at $1.80/sh
-
-
-
-
-
-
-
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
-
-
-
-
-
-
-
Tenax Therapeutics (TENX) Granted US Patent for Subcutaneous Use of Levosimendan
-
-
-
-
-
-
-
Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
-
327,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

